Modulation of Multidrug Resistance Gene Expression by Coumarin Derivatives in Human Leukemic Cells. 2017

Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.

The presence of multidrug resistance (MDR) in tumor cells is considered as the major cause of failure of cancer chemotherapy. The mechanism responsible for the phenomenon of multidrug resistance is explained, among others, as overexpression of membrane transporters primarily from the ABC family which actively remove cytostatics from the tumor cell. The effect of 20 coumarin derivatives on the cytotoxicity and expression of MDR1, MRP1, BCRP, and LRP genes (encoding proteins responsible for multidrug resistance) in cancer cells was analyzed in the study. The aim of this research included determination of IC10 and IC50 values of selected coumarin derivatives in the presence and absence of mitoxantrone in leukemia cells and analysis of changes in the expression of genes involved in multidrug resistance: MDR1, MRP, LRP, and BCRP after 24-hour exposure of the investigated cell lines to selected coumarins in the presence and absence of mitoxantrone in IC10 and IC50 concentrations. The designed research was conducted on 5 cell lines derived from the human hematopoietic system: CCRF/CEM, CEM/C1, HL-60, HL-60/MX1, and HL-60/MX2. Cell lines CEM/C1, HL-60/MX1, and HL-60/MX2 exhibit a multidrug resistance phenotype.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D003374 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. 1,2-Benzopyrone Derivatives,1,2-Benzopyrones,Coumarin Derivative,Coumarine,1,2-Benzo-Pyrones,Benzopyran-2-ones,Coumarin Derivatives,Coumarines,1,2 Benzo Pyrones,1,2 Benzopyrone Derivatives,1,2 Benzopyrones,Benzopyran 2 ones,Derivative, Coumarin,Derivatives, 1,2-Benzopyrone,Derivatives, Coumarin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015973 Gene Expression Regulation, Leukemic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia. Leukemic Gene Expression Regulation,Regulation of Gene Expression, Leukemic,Regulation, Gene Expression, Leukemic
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
August 1993, Endocrinology,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
February 1999, Bioorganic & medicinal chemistry letters,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
January 2007, Anticancer research,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
October 2017, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
May 2009, Leukemia research,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
August 1992, FEBS letters,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
February 2005, Toxicology and applied pharmacology,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
January 1995, Molecular pharmacology,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
March 2000, Chinese medical journal,
Tomasz Kubrak, and Anna Bogucka-Kocka, and Łukasz Komsta, and Daniel Załuski, and Jacek Bogucki, and Dariusz Galkowski, and Robert Kaczmarczyk, and Marcin Feldo, and Maria Cioch, and Janusz Kocki
April 2004, BMC cancer,
Copied contents to your clipboard!